Drug
Inhaled AR 501
Inhaled AR 501: highest development phase Phase 1/2, developed by Aridis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Aridis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Inhaled AR-501 NCT03669614 | Phase 1/2 | Cystic Fibrosis |
Latest
No recent events.
Follow Inhaled AR 501 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.